Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, Ulcerative colitis, and Crohn’s disease.
It targets interleukin 23A (IL-23A).
It is given as a subcutaneous injection.
Pregnancy category AU: B1
The most common side effects include upper respiratory infections.
Injection site reactions such as redness and pain have been rare uncommon, reported in approximately 0.8% of cases.
In a head to head clinical trial of risankizumab and uzstekinumbinvolving patients with moderate to severe Crohn’s disease who had unacceptable side effects with anti-TNF therapy or inadequate response to such therapy. This agent was not inferior to ustekizumab with respect to clinical remission at 24 weeks and superior with respect to endoscopic remission at week 48.
Compared with placebo, risankizumab improved clinical remission rates in an induction trial and in a maintenance trial for patients with moderate to severe active ulcerative colitis (COMMAND study group).